67. Therapeutic duplication would be a concern for a patient prescribed which of the following medications, if also receiving another medication with similar effects?
Answer: A
Therapeutic duplication would be a concern for a patient prescribed doxazosin.
Doxazosin is an alpha-1 adrenergic blocker used primarily to treat hypertension and benign prostatic hyperplasia. If a patient is prescribed doxazosin in conjunction with another medication that also has similar effects on blood pressure or urinary symptoms, it poses a risk of therapeutic duplication, leading to increased side effects and potential complications.
A) doxazosin.
Doxazosin is directly related to therapeutic duplication concerns because it has overlapping effects with other antihypertensive agents and medications used for similar urinary symptoms. Concurrent use with another alpha-1 blocker or hypotensive drug could amplify the therapeutic effects, resulting in adverse outcomes such as hypotension or excessive cardiovascular effects.
B) guaifenesin.
Guaifenesin is an expectorant primarily used to alleviate cough by thinning mucus. It does not have similar therapeutic effects to doxazosin, thus it is not associated with therapeutic duplication in the context of hypertension or urinary treatment. Therefore, it is not a concern when prescribed alongside doxazosin.
C) tamoxifen.
Tamoxifen is a selective estrogen receptor modulator used in breast cancer treatment. While it is an important medication, it does not share similar effects with doxazosin and does not pose a risk of therapeutic duplication. Therefore, it is not relevant in this context.
D) baclofen.
Baclofen is a muscle relaxant used to treat spasticity. Like tamoxifen, it does not have overlapping effects with doxazosin, and thus does not raise concerns about therapeutic duplication. It serves a different therapeutic purpose and does not interact with the mechanisms of action of doxazosin.
Conclusion
Doxazosin is the key medication that raises concerns for therapeutic duplication when combined with another agent that has similar effects, particularly in managing blood pressure or urinary symptoms. The other options—guaifenesin, tamoxifen, and baclofen—do not share similar therapeutic effects with doxazosin, making them irrelevant to the issue of therapeutic duplication in this scenario.